vs
亨廷顿·英格尔斯工业（HII）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
亨廷顿·英格尔斯工业的季度营收约是百利高的1.5倍（$1.7B vs $1.1B），亨廷顿·英格尔斯工业净利率更高（8.9% vs -127.8%，领先136.8%），亨廷顿·英格尔斯工业同比增速更快（13.8% vs -2.5%），百利高自由现金流更多（$148.6M vs $-461.0M），过去两年百利高的营收复合增速更高（1.3% vs -25.2%）
亨廷顿·英格尔斯工业（简称HII）是美国规模最大的军用造船企业，同时面向政府及行业合作伙伴提供专业服务。公司于2011年3月31日从诺斯罗普·格鲁曼公司分拆成立，在防务装备建造及配套服务领域拥有深厚技术积累与行业资源。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
HII vs PRGO — 直观对比
营收规模更大
HII
是对方的1.5倍
$1.1B
营收增速更快
HII
高出16.3%
-2.5%
净利率更高
HII
高出136.8%
-127.8%
自由现金流更多
PRGO
多$609.6M
$-461.0M
两年增速更快
PRGO
近两年复合增速
-25.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7B | $1.1B |
| 净利润 | $149.0M | $-1.4B |
| 毛利率 | — | 32.6% |
| 营业利润率 | 9.3% | -116.0% |
| 净利率 | 8.9% | -127.8% |
| 营收同比 | 13.8% | -2.5% |
| 净利润同比 | — | -3093.9% |
| 每股收益（稀释后） | $3.79 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HIIPRGO
| Q1 26 | $1.7B | — | ||
| Q4 25 | $3.5B | $1.1B | ||
| Q3 25 | $3.2B | $1.0B | ||
| Q2 25 | $3.1B | $1.1B | ||
| Q1 25 | $2.7B | $1.0B | ||
| Q4 24 | $3.0B | $1.1B | ||
| Q3 24 | $2.7B | $1.1B | ||
| Q2 24 | $3.0B | $1.1B |
净利润HIIPRGO
| Q1 26 | $149.0M | — | ||
| Q4 25 | $159.0M | $-1.4B | ||
| Q3 25 | $145.0M | $7.5M | ||
| Q2 25 | $152.0M | $-8.4M | ||
| Q1 25 | $149.0M | $-6.4M | ||
| Q4 24 | $123.0M | $-44.4M | ||
| Q3 24 | $101.0M | $-21.0M | ||
| Q2 24 | $173.0M | $-108.4M |
毛利率HIIPRGO
| Q1 26 | — | — | ||
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% |
营业利润率HIIPRGO
| Q1 26 | 9.3% | — | ||
| Q4 25 | 4.9% | -116.0% | ||
| Q3 25 | 5.0% | 7.0% | ||
| Q2 25 | 5.3% | 4.3% | ||
| Q1 25 | 5.9% | 4.5% | ||
| Q4 24 | 3.7% | 10.0% | ||
| Q3 24 | 3.0% | 7.4% | ||
| Q2 24 | 6.3% | -2.5% |
净利率HIIPRGO
| Q1 26 | 8.9% | — | ||
| Q4 25 | 4.6% | -127.8% | ||
| Q3 25 | 4.5% | 0.7% | ||
| Q2 25 | 4.9% | -0.8% | ||
| Q1 25 | 5.4% | -0.6% | ||
| Q4 24 | 4.1% | -3.9% | ||
| Q3 24 | 3.7% | -1.9% | ||
| Q2 24 | 5.8% | -10.2% |
每股收益（稀释后）HIIPRGO
| Q1 26 | $3.79 | — | ||
| Q4 25 | $4.06 | $-10.23 | ||
| Q3 25 | $3.68 | $0.05 | ||
| Q2 25 | $3.86 | $-0.06 | ||
| Q1 25 | $3.79 | $-0.05 | ||
| Q4 24 | $3.15 | $-0.32 | ||
| Q3 24 | $2.56 | $-0.15 | ||
| Q2 24 | $4.38 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $216.0M | — |
| 总债务越低越好 | $2.7B | — |
| 股东权益账面价值 | $5.1B | $2.9B |
| 总资产 | $12.5B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.52× | — |
8季度趋势，按日历期对齐
现金及短期投资HIIPRGO
| Q1 26 | $216.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $432.1M | ||
| Q2 25 | — | $454.2M | ||
| Q1 25 | — | $409.9M | ||
| Q4 24 | — | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M |
总债务HIIPRGO
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益HIIPRGO
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.1B | $2.9B | ||
| Q3 25 | $5.0B | $4.4B | ||
| Q2 25 | $4.9B | $4.5B | ||
| Q1 25 | $4.8B | $4.4B | ||
| Q4 24 | $4.7B | $4.3B | ||
| Q3 24 | $4.2B | $4.6B | ||
| Q2 24 | $4.2B | $4.5B |
总资产HIIPRGO
| Q1 26 | $12.5B | — | ||
| Q4 25 | $12.7B | $8.5B | ||
| Q3 25 | $12.3B | $10.1B | ||
| Q2 25 | $12.1B | $10.1B | ||
| Q1 25 | $12.1B | $9.8B | ||
| Q4 24 | $12.1B | $9.6B | ||
| Q3 24 | $11.1B | $11.2B | ||
| Q2 24 | $11.3B | $10.4B |
负债/权益比HIIPRGO
| Q1 26 | 0.52× | — | ||
| Q4 25 | 0.53× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-390.0M | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $-461.0M | $148.6M |
| 自由现金流率自由现金流/营收 | -27.7% | 13.4% |
| 资本支出强度资本支出/营收 | 4.4% | 2.4% |
| 现金转化率经营现金流/净利润 | -2.62× | — |
| 过去12个月自由现金流最近4个季度 | $795.0M | $145.1M |
8季度趋势，按日历期对齐
经营现金流HIIPRGO
| Q1 26 | $-390.0M | — | ||
| Q4 25 | $650.0M | $175.4M | ||
| Q3 25 | $118.0M | $51.7M | ||
| Q2 25 | $823.0M | $75.9M | ||
| Q1 25 | $-395.0M | $-64.5M | ||
| Q4 24 | $391.0M | $312.6M | ||
| Q3 24 | $213.0M | $42.2M | ||
| Q2 24 | $-9.0M | $9.5M |
自由现金流HIIPRGO
| Q1 26 | $-461.0M | — | ||
| Q4 25 | $516.0M | $148.6M | ||
| Q3 25 | $13.0M | $29.8M | ||
| Q2 25 | $727.0M | $56.7M | ||
| Q1 25 | $-462.0M | $-90.0M | ||
| Q4 24 | $277.0M | $274.9M | ||
| Q3 24 | $125.0M | $15.1M | ||
| Q2 24 | $-99.0M | $-18.9M |
自由现金流率HIIPRGO
| Q1 26 | -27.7% | — | ||
| Q4 25 | 14.8% | 13.4% | ||
| Q3 25 | 0.4% | 2.9% | ||
| Q2 25 | 23.6% | 5.4% | ||
| Q1 25 | -16.9% | -8.6% | ||
| Q4 24 | 9.2% | 24.2% | ||
| Q3 24 | 4.5% | 1.4% | ||
| Q2 24 | -3.3% | -1.8% |
资本支出强度HIIPRGO
| Q1 26 | 4.4% | — | ||
| Q4 25 | 3.9% | 2.4% | ||
| Q3 25 | 3.3% | 2.1% | ||
| Q2 25 | 3.1% | 1.8% | ||
| Q1 25 | 2.5% | 2.4% | ||
| Q4 24 | 3.8% | 3.3% | ||
| Q3 24 | 3.2% | 2.5% | ||
| Q2 24 | 3.0% | 2.7% |
现金转化率HIIPRGO
| Q1 26 | -2.62× | — | ||
| Q4 25 | 4.09× | — | ||
| Q3 25 | 0.81× | 6.89× | ||
| Q2 25 | 5.41× | — | ||
| Q1 25 | -2.65× | — | ||
| Q4 24 | 3.18× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | -0.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HII
暂无分部数据
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
